Global Lipid Nanoparticles (LNP) Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Lipid Nanoparticles (LNP) Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Lipid Nanoparticles (LNP) are nanoparticles composed of lipids. They are a novel pharmaceutical drug delivery system (and part of nanoparticle drug delivery), and a novel pharmaceutical formulation. Lipid nanoparticles (LNP) are the most clinically advanced non-viral gene delivery system. Lipid nanoparticles safely and effectively deliver nucleic acids, overcoming a major barrier preventing the development and use of genetic medicines. LNP as a drug delivery vehicle were first approved in 2018 for the siRNA drug Onpattro.

Market Overview:

The latest research study on the global Lipid Nanoparticles (LNP) market finds that the global Lipid Nanoparticles (LNP) market reached a value of USD 694.48 million in 2022. It’s expected that the market will achieve USD 1316.9 million by 2028, exhibiting a CAGR of 11.25% during the forecast period.

Use in COVID-19 Vaccines

Currently, companies have developed various delivery technologies based on different principles. Among them, LNP is currently the most mainstream and only approved delivery technology. As early as 2018, the world's first approved siRNA drug Patisiran applied this technology. In this COVID-19 epidemic, it was once again favored by Moderna, BioNTech and many other companies and developed and applied in the new crown vaccine.
In addition, as of June 21, 2022, the number of confirmed COVID-19 cases worldwide has exceeded 540 million. The outbreak of COVID-19 and the continuous acceleration of innovative technologies such as mRNA vaccines into clinical applications, the corresponding Lipid Nanoparticles (LNP) drug delivery technology has also ushered in rapid development, and almost all approved mRNA vaccines use Lipid Nanoparticles (LNP) system. The use of Lipid Nanoparticles (LNP) in COVID-19 vaccines has led to a significant increase in the demand for Lipid Nanoparticles (LNP) in the market.

High technology content, limiting the mass production of Lipid Nanoparticles (LNP)

Lipid Nanoparticles (LNP) synthesis is a complex multi-step process. Traditional LNP fabrication methods (including but not limited to thin-film hydration, reverse-phase evaporation, solvent injection, and detergent removal) typically yield large (>100 nm) heterogeneous particles with low encapsulation rates, requiring additional steps to downscale dimensions, such as extrusion or sonication. Therefore, relatively few companies in the world actually have the equipment and facilities to manufacture Lipid Nanoparticles (LNPs) or special ionizable cationic lipids.
Another problem has to do with patents. Since Lipid Nanoparticles (LNP) is a new biotechnology, scaling up its production has led to some intellectual property disputes. For example, Moderna was involved in a dispute with biotech company Arbutus over patents related to Lipid Nanoparticles (LNP).

Threat of New Entrants

Profitable industries that yield high returns will attract new firms. New entrants eventually will decrease profitability for other firms in the industry. Unless the entry of new firms can be made more difficult by incumbents, abnormal profitability will fall towards zero (perfect competition), which is the minimum level of profitability required to keep an industry in business.
A company's power is also affected by the force of new entrants into its market. The less time and money it costs for a competitor to enter market and become a competitive competitor, the larger the possibility that existing company’s’ position may be significantly weakened. The barrier of entry for Lipid Nanoparticles (LNP) is very high, and if new entrants with strong capital background, skilled team and mature sales channels will pose threat to the existing companies.

Region Overview:

Geographically, North America held the largest market share – 61.54% in 2022.

Company Overview:

Evonik Industries is one of the major players operating in the Lipid Nanoparticles (LNP) market, holding a share of 24.21% in 2023.

Evonik Industries

The Health Care business of Evonik, a specialty chemicals company headquartered in Essen, Germany, serves as a leading and integrated service provider of products and technologies for mRNA-based medicines. Evonik has been supplying major pharmaceutical companies worldwide with the lipids needed for use with mRNA active ingredients (messenger ribonucleic acid). Lipids are critical components in the formulation of nucleic acid therapies.

Merck KGaA

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.

Segmentation Overview:

Among different product types, mRNA-lipid Nanoparticle segment is anticipated to contribute the largest market share in 2028.

mRNA-lipid Nanoparticle

Messenger RNA (abbreviated mRNA) is a type of single-stranded RNA involved in protein synthesis. mRNA is made from a DNA template during the process of transcription. The role of mRNA is to carry protein information from the DNA in a cell’s nucleus to the cell’s cytoplasm (watery interior), where the protein-making machinery reads the mRNA sequence and translates each three-base codon into its corresponding amino acid in a growing protein chain. mRNA-lipid Nanoparticles are lipid nanoparticles containing mRNA.

siRNA-lipid Nanoparticle

Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA at first non-coding RNA molecules, typically 20-24 (normally 21) base pairs in length, similar to miRNA, and operating within the RNA interference (RNAi) pathway. It interferes with the expression of specific genes with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. siRNA-lipid Nanoparticle are lipid nanoparticles containing siRNA.

Application Overview:

The market's largest segment by application is the segment Vaccines, with a market share of 78.38% in 2022.

Key Companies in the global Lipid Nanoparticles (LNP) market covered in Chapter 3:

Evonik Industries
Alnylam
Corden Pharma
Exelead
Genevant Sciences
Merck KGaA
Avanti Polar Lipids

In Chapter 4 and Chapter 14.2, on the basis of types, the Lipid Nanoparticles (LNP) market from 2018 to 2029 is primarily split into:

mRNA-lipid Nanoparticle
siRNA-lipid Nanoparticle
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Lipid Nanoparticles (LNP) market from 2018 to 2029 covers:

Vaccines
Scientific Research
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)